

Supplementary Table S1. *Clinical characteristics of patients with SLE and control individuals in the discovery and replication cohorts.*

	Discovery		Replication	
	Patients	Controls	Patients	Controls
Individuals, n*	347	400	201	187
Women, n (%)	300 (86.5)	351 (87.7)	175 (87.1)	174 (93.0)
Age at blood sampling, years (mean \pm s.d.)	47.0 \pm 17.2	47.1 \pm 13.2	48.7 \pm 14.8	48.8 \pm 14.9
Age at diagnosis, years (mean \pm s.d.)	34.7 \pm 17.0		34.7 \pm 14.5	
Disease duration, years (mean \pm s.d.)	12.3 \pm 11.4		14.0 \pm 12.3	
The 1982 ACR criteria positive patients,				
total n (%), women n (%)				
Malar rash	188 (54.2), 169 (56.3)		103 (51.2), 94 (50.3)	
Discoid rash	76 (21.9), 65 (21.7)		34 (16.9), 32 (17.1)	
Photosensitivity	203 (58.5), 183 (61.0)		134 (66.7), 125 (66.8)	
Oral ulcers	66 (19.0), 62 (20.7)		49 (24.4), 45 (24.1)	
Non-erosive arthritis	254 (73.2), 220 (73.3)		166 (82.6), 146 (78.1)	
Serositis	154 (44.4), 124 (41.3)		82 (40.8), 66 (35.3)	
Renal disorder	103 (29.7), 81 (27)		77 (38.3), 60 (32.1)	
Neurological disorder	20 (5.8), 16 (5.3)		21 (10.4), 18 (9.6)	
Hematological disorder	211 (64.0), 180 (60.0)		140 (69.6), 123 (65.8)	
Immunological disorder	211 (64.0), 174 (58.0)		136 (67.7), 118 (63.1)	
Antinuclear antibody positive	340 (98.0), 293 (97.7)		198 (98.5), 172 (92.0)	
Treatment positive patients [†] , total n (%),				
women n (%)				
Glucocorticoids	215 (62.0), 190 (63.3)		111 (55.2), 94 (53.7)	
Chloroquines [‡]	166 (47.8), 148 (49.3)		73 (36.3), 61 (.34.9)	
Azathioprine	55 (15.8), 49 (16.3)		37 (18.4), 34 (19.4)	
Mycophenolate mofetil	36 (10.4), 28 (9.3)		18 (9.0), 10 (5.7)	
Methotrexate	22 (6.3), 21 (7.0)		8 (4.0), 8 (4.6)	
Other immunosuppressive drugs [§]	16 (4.6), 14 (4.7)		39 (19.4), 35 (20.0)	
Disease activity [†] , total score (mean \pm s.d.)				
SLEDAI-2K [^]	3.1 \pm 4.8		n.a.	
SLAM [#]	n.a.		6.6 \pm 4.2	
Active SLE ^{†**} , total n (%), women n (%)				
	68 (19.9), 58 (19.7)		42 (21.0), 40 (23.0)	

*Number of individuals after quality control in the methylation analysis

[†] Data not available for all patients

[‡] Chloroquine or hydroxychloroquine

[§] Sirolimus (discovery n=8; replication n=na), Rituximab (discovery n=4; replication n=17), Cyclosporine (discovery n=2; replication n=na), Cyclophosphamide (discovery n=1; replication n=22), Tacrolimus (discovery n=1; replication n=na)

[^]SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000

[#] SLAM, Systemic Lupus Activity Measure

**SLEDAI-2K \geq 5 in the discovery cohort and SLAM \geq 10 in the replication cohort was used to define more active SLE
n.a., not available